JP2009543806A - ｇＣ１ｑＲ／ｐ３２を標的化するための方法および組成物 - Google Patents

ｇＣ１ｑＲ／ｐ３２を標的化するための方法および組成物 Download PDF

Info

Publication number
JP2009543806A
JP2009543806A JP2009519695A JP2009519695A JP2009543806A JP 2009543806 A JP2009543806 A JP 2009543806A JP 2009519695 A JP2009519695 A JP 2009519695A JP 2009519695 A JP2009519695 A JP 2009519695A JP 2009543806 A JP2009543806 A JP 2009543806A
Authority
JP
Japan
Prior art keywords
lyp
receptor
gc1q
composition
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009519695A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009543806A5 (enExample
Inventor
エルッキ ルオスラーティ，
ヴァレンティナ フォーガル，
Original Assignee
バーナム インスティテュート フォー メディカル リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バーナム インスティテュート フォー メディカル リサーチ filed Critical バーナム インスティテュート フォー メディカル リサーチ
Publication of JP2009543806A publication Critical patent/JP2009543806A/ja
Publication of JP2009543806A5 publication Critical patent/JP2009543806A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2009519695A 2006-07-13 2007-07-12 ｇＣ１ｑＲ／ｐ３２を標的化するための方法および組成物 Pending JP2009543806A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80725506P 2006-07-13 2006-07-13
PCT/US2007/073372 WO2008100328A2 (en) 2006-07-13 2007-07-12 METHODS AND COMPOSITIONS FOR TARGETING gC1qR/p32

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012282110A Division JP2013060463A (ja) 2006-07-13 2012-12-26 ｇＣ１ｑＲ／ｐ３２を標的化するための方法および組成物

Publications (2)

Publication Number Publication Date
JP2009543806A true JP2009543806A (ja) 2009-12-10
JP2009543806A5 JP2009543806A5 (enExample) 2010-09-02

Family

ID=39690654

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009519695A Pending JP2009543806A (ja) 2006-07-13 2007-07-12 ｇＣ１ｑＲ／ｐ３２を標的化するための方法および組成物
JP2012282110A Pending JP2013060463A (ja) 2006-07-13 2012-12-26 ｇＣ１ｑＲ／ｐ３２を標的化するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012282110A Pending JP2013060463A (ja) 2006-07-13 2012-12-26 ｇＣ１ｑＲ／ｐ３２を標的化するための方法および組成物

Country Status (5)

Country Link
US (2) US8178104B2 (enExample)
EP (1) EP2043696B1 (enExample)
JP (2) JP2009543806A (enExample)
CA (1) CA2657649A1 (enExample)
WO (1) WO2008100328A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010514839A (ja) * 2007-01-03 2010-05-06 バーナム インスティテュート フォー メディカル リサーチ クロット結合化合物に関連する方法および組成物
KR20230047804A (ko) * 2021-10-01 2023-04-10 강원대학교산학협력단 p32 유래 펩타이드를 포함하는 심혈관 질환 예방 또는 치료용 조성물
KR20230047805A (ko) * 2021-10-01 2023-04-10 강원대학교산학협력단 알기나제 유래 펩타이드를 포함하는 심혈관 질환 예방 또는 치료용 조성물

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1583562T3 (da) * 2003-01-06 2011-09-19 Angiochem Inc Angiopep-1, beslægtede forbindelser og anvendelser deraf
US9365634B2 (en) * 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US9732320B2 (en) 2008-01-18 2017-08-15 The Brigham And Women's Hospital, Inc. Selective differentiation, identification, and modulation of human TH17 cells
US20110245107A1 (en) * 2008-01-18 2011-10-06 The Brigham And Women's Hospital, Inc. Selective differentiation, identification, amd modulation of human th17 cells
AU2009238187B2 (en) 2008-04-18 2014-03-06 Angiochem Inc. Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
CA2740316A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
CA2740317A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Etoposide and doxorubicin conjugates for drug delivery
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
BRPI0922611A2 (pt) 2008-12-17 2018-11-06 Angiochem Inc inibidores de metaloproteína de matriz de membrana tipo 1 e usos dos mesmos
US8883153B2 (en) 2009-03-27 2014-11-11 The Research for The State University of New York Methods for preventing and treating angioedema
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
BRPI1015424B1 (pt) * 2009-06-22 2022-01-18 Burnham Institute For Medical Research Composição compreendendo um elemento cendr e uma co-composição e composição para uso no reforço da internalização, penetração, ou ambas, de uma co-composição
EP2448965A4 (en) 2009-07-02 2015-02-11 Angiochem Inc MULTIMEPEPTID CONJUGATES AND ITS USES
WO2011127405A1 (en) 2010-04-08 2011-10-13 Sanford-Burnham Medical Research Institute Methods and compositions for enhanced delivery of compounds
CA2837588A1 (en) 2011-05-31 2012-12-06 Airware, Inc. Re-calibration of ab ndir gas sensors
US9061079B2 (en) * 2011-06-24 2015-06-23 Sanford-Burnham Medical Research Institute Peptides that home to atherosclerotic plaques and methods of use
GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method
US10669311B2 (en) 2015-04-23 2020-06-02 Sanford Burnham Prebys Medical Discovery Institute Targeted delivery system and methods of use therefor
DK3307326T3 (da) 2015-06-15 2020-10-19 Angiochem Inc Fremgangsmåder til behandling af leptomeningeal karcinomatose
KR102061924B1 (ko) 2015-11-24 2020-01-02 강원대학교산학협력단 Ｐ３２ 저해제를 포함하는 심혈관 질환 예방 또는 치료용 조성물
AU2019347666B2 (en) * 2018-09-28 2025-10-02 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
WO2021247769A1 (en) * 2020-06-02 2021-12-09 Dynamicure Biotechnology Llc Anti-cd93 constructs and uses thereof
AU2021315665A1 (en) * 2020-07-29 2023-03-16 Dynamicure Biotechnology Llc Anti-CD93 constructs and uses thereof
WO2023064887A1 (en) 2021-10-15 2023-04-20 The Board Of Trustees Of The University Of Illinois Mechanochemical dynamic therapy for focal cancer treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087499A1 (en) * 2001-11-08 2004-05-06 Pirjo Laakkonen Peptides that home to tumor lymphatic vasculature and methods of using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3040693A (en) * 1961-02-20 1962-06-26 George F Bunker Oar paddle, boat hook and oar
US5691447A (en) * 1995-03-24 1997-11-25 Tanox Biosystems, Inc. GC1q receptor, HIV-1 gp120 region binding thereto, and related peptides and targeting antibodies
WO2001002556A2 (de) * 1999-06-30 2001-01-11 Max-Delbrück-Centrum für Molekulare Medizin Mittel zur diagnose, prognose und therapie maligner erkrankungen
DE60230822D1 (de) * 2001-11-08 2009-02-26 Burnham Inst Peptide mit homing für lymphgefässtumor und ihre verwendung
WO2004106360A2 (en) * 2003-05-23 2004-12-09 Mount Sinai School Of Medicine Of New York University Viral vectors with improved properties

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087499A1 (en) * 2001-11-08 2004-05-06 Pirjo Laakkonen Peptides that home to tumor lymphatic vasculature and methods of using same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6012036697; ＮＡＴＵＲＥ　ＭＥＤＩＣＩＮＥ Ｖｏｌ．８，Ｎｏ．７, 2002, ｐ．７５１-７５５ *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010514839A (ja) * 2007-01-03 2010-05-06 バーナム インスティテュート フォー メディカル リサーチ クロット結合化合物に関連する方法および組成物
KR20230047804A (ko) * 2021-10-01 2023-04-10 강원대학교산학협력단 p32 유래 펩타이드를 포함하는 심혈관 질환 예방 또는 치료용 조성물
KR20230047805A (ko) * 2021-10-01 2023-04-10 강원대학교산학협력단 알기나제 유래 펩타이드를 포함하는 심혈관 질환 예방 또는 치료용 조성물
KR102739370B1 (ko) 2021-10-01 2024-12-05 강원대학교산학협력단 p32 유래 펩타이드를 포함하는 심혈관 질환 예방 또는 치료용 조성물
KR102841756B1 (ko) 2021-10-01 2025-08-01 강원대학교산학협력단 알기나제 유래 펩타이드를 포함하는 심혈관 질환 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
CA2657649A1 (en) 2008-08-21
EP2043696A2 (en) 2009-04-08
JP2013060463A (ja) 2013-04-04
US20080014143A1 (en) 2008-01-17
EP2043696A4 (en) 2012-01-04
WO2008100328A2 (en) 2008-08-21
EP2043696B1 (en) 2015-02-25
US8178104B2 (en) 2012-05-15
WO2008100328A3 (en) 2009-01-08
US20120219502A1 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
US8178104B2 (en) Methods and compositions for targeting gC1qR/p32
US8753604B2 (en) Methods and compositions for synaphically-targeted treatment for cancer
US8329859B2 (en) Peptides that home to tumor lymphatic vasculature and methods of using same
US7488792B2 (en) Collagen-binding molecules that selectively home to tumor vasculature and methods of using same
JP6331030B2 (ja) アネキシン１結合化合物に関する方法および組成物
CA2638911C (en) Methods and compositions related to targeting tumors and wounds
WO2014031174A1 (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
US12195558B2 (en) Targeted delivery system and methods of use therefor
CA2380888A1 (en) Treatment of metastatic disease
JP2011525491A (ja) Ｃｒｋｌ標的化ペプチド
JP7608336B2 (ja) 中枢神経系原発リンパ腫の併用治療
JP2013515008A (ja) 凝血塊結合化合物に関連する方法および組成物
CN101160402B (zh) 肿瘤特异性抗体和细胞表面蛋白质
JP2005514348A (ja) 腫瘍リンパ性脈管構造を目指すペプチドおよびその使用方法
US5800814A (en) Method for inhibition of breast tumor growth

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100622

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120713

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121009

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121016

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121112

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121212

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130329

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130626

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130718

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140107